Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Zoledronic acid (ZA) has been shown to inhibit prostate tumor growth in vitro and have beneficial effects in patients with advanced prostate cancer (CaP). The aim of this study was to determine whether ZA exhibits direct anti-tumor effects on CaP cells in vivo. To distinguish the effects of inhibition of osteolysis and direct anti-tumor activity of ZA in vivo, we compared the results of treatment with ZA and osteoprotegerin (Fc-OPG), which inhibits osteolysis, but without significant direct anti-tumor effects. In vitro Fc-OPG had no significant effects on C4-2 proliferation, whereas ZA decreased proliferation. However, both agents decreased tumor growth in bone. Moreover, both increased bone volume and prevented the overall decreases in BMD associated with growth of C4-2 cells in bone. Our study provides novel and significant observations that the in vivo effects of ZA are consistent with indirect effects mediated by osteoclasts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the experimental use of OPG in numerous bone metastasis models has provided substantial evidence that turnover suppression is the principal means by which bisphosphonates and RANKL inhibitors reduce skeletal tumor burden (340,(343)(344)(345).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
In the citing paper
“Although OPG had no significant effects on the proliferation of cultured C4 -2 cells, high doses of ZOL (10 -100 m) were associated with significant C4 -2 growth suppression.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
In the citing paper
“OPG and ZOL both significantly decreased skeletal tumor burden when delivered in a preventative manner, whereas only OPG caused significant suppression of skeletal tumor burden when treatment was delayed until lytic tumors were established (344).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
In the citing paper
“OPG and ZOL both suppressed tumor-associated osteolysis and decreased osteoclast surfaces in tumor-bearing bones (344).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [344]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586
Zhang, J., Dai, J., Qi, Y., Lin, D.-L., Smith, P., Strayhorn, C., Mizokami, A., Fu, Z., Westman, J., & Keller, E. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11685 · Cited by 452
Self-citationBisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee, M. V., Fong, E. D. M., Singer, F. R., & Guenette, R. S. (2001) · PubMed · Cited by 364
Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 318
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Zheng, Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J. R. K., Seibel, M. J., & Dunstan, C. R. (2007) · Bone · doi:10.1016/j.bone.2006.09.016 · Cited by 82
Miller, R. E., Roudier, M. P., Jones, J. C., Armstrong, A. P., Canon, J. R., & Dougall, W. C. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0046 · Cited by 85
Brubaker, K. D., Brown, L. G., Vessella, R. L., & Corey, E. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-15 · Cited by 80
Self-citation
Metadata
- Authors
- Quinn, J. E., Brown, L. G., Zhang, J., Keller, E. T., Vessella, R. L., & Corey, E.
- Affiliations
- University of Washington (US)
- University of Michigan (US)
- Corresponding author
- Corey, E
- Venue
- Prostate Cancer and Prostatic Diseases
- Published
- 2005-07-05
- Volume
- 8
- Issue
- 3
- Pages
- 253-259
- ISSN
- 1365-7852 (ISSN-L)
- 1476-5608
- OpenAlex
- W2027402812
- Cited by
- 29
- References
- 26
- Citations by year
- 2018: 1 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 3
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Prostate Cancer and Prostatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Amgen
- Novartis
- National Institutes of Health
- Novartis Pharma
- National Cancer Institute (P01 CA85859-01A, P01CA085859)
- DOD Prostate Cancer Research Program
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- zoledronic acid, prostate cancer, bone metastasis, osteolysis, osteoclasts, tumor cell proliferation, bone volume, bone mineral density, bisphosphonates
- MeSH terms
- Zoledronic Acid, Animals, Antibodies, Antineoplastic Agents, Bone Neoplasms, Densitometry, Diphosphonates, Glycoproteins, Humans, Imidazoles, Immunoglobulin Fc Fragments, Male, Neoplasm Metastasis, Osteoclasts, Osteolysis, Prostatic Neoplasms, Tibia, Time Factors, Bone Density, Mice, SCID, Apoptosis, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Cell Proliferation, Bone Density Conservation Agents, Mice, Osteoprotegerin, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. https://app.cochat.ai/papers/10.1038/sj.pcan.4500815
- The paper
- Quinn, J. E., Brown, L. G., Zhang, J., Keller, E. T., Vessella, R. L., & Corey, E. (2005). Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/sj.pcan.4500815
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.